November 18, 2020
Why Kazia Therapeutics isAustralia’s biotech shining star
By Marc Sinatra | More Articles by Marc Sinatra
Kazia Therapeutics share price has been driven by strong buying in their US-listed ADRs with the company’s market capitalisation moving from $75m to $200m since the Corporate Connect Research report was released. Corporate Connect biotech analyst Marc Sinatra updates the market post the ASX announcement by Kazia of further Paxalisib data.For full details refer to the research report below or click here to download your copy.
- Forums
- ASX - By Stock
- Kazia Share Price
SHARESNovember 18, 2020Why Kazia Therapeutics isAustralia’s...
-
- There are more pages in this discussion • 584 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)